Brief: Dimerix Says FDA Confirms Inclusion Of Paediatric Patients In Action3 Study Of DMX-200 For FSGS
11/01/2023 23:55
Jan 12 (Reuters) - Dimerix Ltd DXB.AX :
* U.S. FDA CONFIRMS INCLUSION OF PAEDIATRIC PATIENTS IN
ACTION3
STUDY OF DMX-200 FOR FSGS
Source text for Eikon: ID:nASX98PnXW
Further company coverage: DXB.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Dimerix
See all newsAustralia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region
Brief: Everest Medicine In Agreement With Dimerix To Develop Commercialize DMX-200 In Greater China, South Korea, And Southeast Asia
Brief: Dimerix Seeks Trading Halt
Brief: Dimerix To Conduct Review Of Action3 Statistical Assumptions